Given the success of immune checkpoint inhibitors and chimeric antigen receptor (CAR) T
cells in clinical settings, the host immune system plays an important role in the recognition …

Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is a threat to the health
of all humans as a prevalent malignancy and is the sixth most common cancer worldwide. It …

Hepatocellular carcinoma (HCC) is a frequent cancer with a high mortality. For early stage
cancer there are potentially curative treatments including local ablation, resection and liver …

Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the fifth
most common cancer worldwide and the second leading cause of cancer-related death …

Simple Summary The incidence of liver cancer is increasing worldwide. When detected
early, the most common form of primary liver cancer (hepatocellular carcinoma, or HCC) can …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. HCC patients may benefit from liver transplantation, hepatic resection …

Primary liver cancer is a common kind of digestive cancers with high malignancy, causing
745,500 deaths each year. Hepatocellular carcinoma is the major pathological type of …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with dismal
prognosis when diagnosed at advanced stages. Surgical resection of the primary tumor or …

Immunotherapy is a promising approach to treating various types of cancers, including
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited …

Introduction: The introduction of immune checkpoint inhibitors has been lately proposed for
the treatment of hepatocellular carcinoma (HCC) with respect to other cancer types. Several …